Next Article in Journal
Identification and Validation of Evolutionarily Conserved Unusually Short Pre-mRNA Introns in the Human Genome
Next Article in Special Issue
Gene Expression Signature in Endemic Osteoarthritis by Microarray Analysis
Previous Article in Journal
Effect of Melatonin on the Extracellular-Regulated Kinase Signal Pathway Activation and Human Osteoblastic Cell Line hFOB 1.19 Proliferation
Previous Article in Special Issue
An Exploratory Pilot Study of Genetic Marker for IgE-Mediated Allergic Diseases with Expressions of FcεR1α and Cε
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2015, 16(5), 10354-10375; doi:10.3390/ijms160510354

Optimal Decision Rules for Biomarker-Based Subgroup Selection for a Targeted Therapy in Oncology

Institute of Medical Biometry and Informatics, University of Heidelberg, INF 305, D-69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Camile S. Farah
Received: 25 February 2015 / Revised: 16 April 2015 / Accepted: 29 April 2015 / Published: 7 May 2015
(This article belongs to the Special Issue Emerging Classes of Biomarkers for Molecular Diagnostics)
View Full-Text   |   Download PDF [167 KB, uploaded 7 May 2015]   |  

Abstract

Throughout recent years, there has been a rapidly increasing interest regarding the evaluation of so-called targeted therapies. These therapies are assumed to show a greater benefit in a pre-specified subgroup of patients—commonly identified by a predictive biomarker—as compared to the total patient population of interest. This situation has led to the necessity to develop biostatistical methods allowing an efficient evaluation of such treatments. Among others, adaptive enrichment designs have been proposed as a solution. These designs allow the selection of the most promising patient population based on an efficacy analysis at interim and restricting recruitment to these patients afterwards. As has recently been shown, the performance of the applied interim decision rule in such a design plays a crucial role in ensuring a successful trial. In this work, we investigate the situation when the primary outcome of the trial is a binary variable. Optimal decision rules are derived which incorporate the uncertainty about the treatment effects. These optimal decision rules are evaluated with respect to their performance in an adaptive enrichment design in terms of correct selection probability and power, and are compared to proposed ad hoc decision rules. Our methods are illustrated by means of a clinical trial example. View Full-Text
Keywords: adaptive designs; subgroup selection; personalized medicine; targeted therapy; biomarker adaptive designs; subgroup selection; personalized medicine; targeted therapy; biomarker
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Krisam, J.; Kieser, M. Optimal Decision Rules for Biomarker-Based Subgroup Selection for a Targeted Therapy in Oncology. Int. J. Mol. Sci. 2015, 16, 10354-10375.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top